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Abstract
Background: Maternal diabetes affects the developing fetal cardiovascular system. Newborn
offspring of diabetic mothers can have a transient cardiomyopathy. We hypothesized that
cardiomyopathic remodeling is associated with activation of the mitogen activated protein kinase
(MAPK) signaling and apoptotic pathways.
Methods: To evaluate the effects of moderate and severe maternal hyperglycemia, pregnant rats
were made diabetic with an injection of 50 mg/kg of streptozotocin. Moderately well controlled
maternal diabetes was achieved with twice daily glucose checks and insulin injections. No insulin
was given to severely diabetic dams. Offspring of moderate and severe diabetic mothers (OMDM
and MSDM, respectively) were studied on postnatal days 1 (NB1) and 21 (NB21). Echocardiograms
were performed to evaluate left ventricular (LV) dimensions and function. Myocardial MAPK and
apoptotic protein levels were measured by Western blot.
Results: OMDM had increased cardiac mass at NB1 compared to controls that normalized at
NB21. OSDM demonstrated microsomia with relative sparing of cardiac mass and a dilated
cardiomyopathy at NB1. In both models, there was a persistent increase in the HW:BW and
significant activation of MAPK and apoptotic pathways at NB21.
Conclusion: The degree of maternal hyperglycemia determines the type of cardiomyopathy seen
in the offspring, while resolution of both the hypertrophic and dilated cardiomyopathies is
associated with activation of MAPK signaling and apoptotic pathways.
Background
Infants of diabetic mothers (IDM) represent a high-risk
group of patients with an increased incidence of perinatal
morbidity and mortality [1]. Even with good maternal
serum glucose control, the offspring are at increased risk
for complex multisystem medical problems including
macrosomia, hypoglycemia, hypocalcaemia, and respira-
tory distress syndrome [2]. Although not commonly seen
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in current medical practice, very poorly controlled gesta-
tional diabetes results in small for gestational age infants
with relative sparing of internal organs such as the heart
and significant multisystem medical problems [3].
The cardiomyopathy seen in very poorly controlled gesta-
tional diabetes is likely different from the hypertrophic
cardiomyopathy (HCM) found in better controlled IDM
[2,4-6]. The HCM seen in infants of well controlled dia-
betic mothers is characterized by asymmetric septal hyper-
trophy with individual myocyte hypertrophy and limited
myofiber disarray [6]. The functional significance of the
HCM is variable, ranging from a clinically insignificant
echocardiographic finding to congestive heart failure as a
result of left ventricular outflow tract obstruction and
diastolic dysfunction [7]. Regardless of severity, the car-
diac hypertrophy is transient, with echocardiographic res-
olution by six months of age [6]. While the morphologic
characteristics of the cardiomyopathy seen in IDM are
well described, the molecular mechanisms regulating its
development and resolution are currently unknown.
The heart is capable of remodeling in response to physio-
logic and pathologic stimulation. The mitogen activated
protein kinase (MAPK) pathways play a key role in the
response of cardiac myocytes to these stressful stimuli
[8,9]. The most studied terminal kinases of these path-
ways: extracellular signal regulated protein kinases (ERK),
c-Jun NH2-terminal kinases (JNK), and p38, activate tran-
scription factors that ultimately affect gene expression
[10]. In general, ERK activation (or phosphorylation) is
pro-growth and has been implicated in hyperplasia of
immature cardiomyocytes and hypertrophy of terminally
differentiated cardiomyocytes [11]. The roles of JNK and
p38 are less clear. In vitro, JNK and p38 activation pro-
motes hypertrophy although in vivo these pathways
appear to prevent hypertrophy [12]. In addition to the
roles these pathways play in cell growth and proliferation,
the MAPK signaling pathways are powerful regulators of
apoptosis [13]. While apoptosis has been implicated in
the development of some forms of cardiomyopathy, its
role in the development and resolution of the HCM seen
in IDM is unknown [14,15].
In order to explore the role of the MAPK and apoptotic
pathways in the development and resolution of the cardi-
omyopathy seen in infants of diabetic mothers, we devel-
oped two rat models of gestational hyperglycemia – one
with very poorly controlled glucose with maternal ketosis
and a second model with moderately well controlled glu-
cose levels and no maternal ketosis. We hypothesized that
the offspring of both the moderately and severely diabetic
mothers would demonstrate a cardiomyopathy whose
postnatal resolution was associated with activation of the
MAPK signaling and apoptotic pathways.
Methods
Animal Preparation
To develop a moderate level of maternal hyperglycemia
(serum glucose in the 200 to 400 mg/dl range with no
maternal ketosis), timed, pregnant Sprague-Dawley rats
obtained from Charles River (Charles River Laboratories,
Wilmington, MA) were injected with 50 mg/kg streptozo-
tocin (STZ) intraperitoneally on day 12 of gestation.
Streptozotocin (Sigma Chemical, St. Louis, MO) was dis-
solved in citrate buffer (pH 4.5) and injected within 5
minutes to prevent its degradation. Serum glucose levels
were monitored twice daily by sampling from tail-nicking
(OneTouch Ultra, LifeScan, Miltitas, CA) and insulin
given twice daily based on a sliding scale. Regular Humu-
lin (Eli Lilly and Company, Indianapolis, IN) was given
for the morning dose (1 – 3 units subcutaneously) and
long-acting Lantus insulin (Aventis Pharmaceuticals, Inc.)
was given in the early evening (1 – 3 units subcutane-
ously). Typically, decreased insulin dosing was needed in
the one to two days prior to delivery. Control pregnant
rats were given the identical volume of citrate buffer with-
out STZ, had serum glucose monitored twice daily, and
given twice daily saline injections. Offspring were studied
at postnatal day 1 (NB1) and postnatal day 21 (NB21).
On the first day of life, all pups to be studied at NB21 were
transferred to foster dams obtained at the same time as the
STZ and sham injected animals whose newborns were
removed. At NB1 and NB21, a subset rat pups were
weighed and then euthanized in a carbon dioxide cham-
ber followed by decapitation for morphometric measure-
ments including body and whole heart weight (Control
NB1: N = 102; OMDM NB1: N = 181; Control NB21: N =
28; OMDM NB21: N = 24).
For the model of severe maternal hyperglycemia with
ketosis, intravenous injections of streptozotocin (50 mg/
kg) or normal saline were given to pregnant rats by Zivic-
Miller Laboratory (Pittsburgh, PA) employees on day 7 of
gestation. Maternal glucose levels were measured on day
15 of gestation and on the day following parturition as
above. The upper limit of the glucometer is 600 mg/dl.
Any reading greater than this value was reported as "high"
by the meter. Any streptozotocin-injected rats that were
not diabetic (greater than 400 mg/dl on day 15 of gesta-
tion) were excluded from the study. Blood was obtained
from a subset of maternal rats to test for the presence of
ketones (Acetest; Bayer Corp, Pillchant IN). Offspring at
NB1 and NB21 were handled as described above. Mor-
phometric measurements were made on a subset of ani-
mals (Control NB1: N = 72; OSDM NB1: N = 37; ControlCardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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NB21: N = 35; OSDM NB21: N = 15). Additional hearts
from both models of maternal hyperglycemia were also
excised and frozen for Western blot analysis.
All procedures were performed within the regulations of
the Animal Welfare Act and the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
and were approved by the University of Iowa Animal Care
and Use Committee.
Echocardiograms
Echocardiography was performed using a Philips Sonos
5500 imager fitted with a 15 MHz linear array probe on
OSDM NB1 (n = 13 control, 6 experimental) and NB21 (n
= 3 control, 6 experimental) rat pups [16,17]. When
OMDM animals were studied, a new imaging system with
better spatial and temporal resolution was available. This
imaging was performed with a Vevo 770 high resolution
ultrasound imaging system (VisualSonics, Inc., Toronto,
Ontario) fitted with a 24 MHz mechanical transducer
(NB1: n = 7 control, 5 experimental; NB21: n = 7 control,
7 experimental). Short-axis images were acquired parallel
to the mitral valve plane so as to obtain the largest cross-
sectional image of the left ventricle that did not contain
the mitral valve. Long-axis views were obtained perpen-
dicular to the mitral valve plane and were deemed opti-
mal when the diastolic apex-to-base length was longest
and when both mitral and aortic valves were visible. Ejec-
tion fraction (EF) and left ventricular mass (LVM) were
determined using Simpson's rule from 2-D images
obtained on the Sonos 5500 and from m-mode images on
the Vevo 770 using analysis packages available on each
system.
Western blots
Immunoblots were prepared as described previously [18].
Briefly, myocardial samples were homogenized in the
presence of protease inhibitors including soybean trypsin
inhibitor, leupeptin, and PMSF in 50 mM Tris/10 mM
EDTA/150 mM NaCl/0.1% mercaptoethanol and then
sonicated for 20 seconds. Following centrifugation, total
protein of the supernatant was quantitated spectrophoto-
metrically. 20 mcg of protein were separated by SDS-
PAGE and transferred to a nitrocellulose membrane.
Membranes were blocked with Odyssey Blocking Buffer
(Part No. 927–40000, Li-Cor Biosciences, Lincoln, NE)
for one hour at room temperature and then incubated in
primary antibody overnight at 5°C. Bound primary anti-
body was detected by incubation with infrared-labeled
secondary antibodies (IRDye 800 or IRDye 700 700DX,
Li-Cor Biotechnology, Lincoln, NE), read, and quantitated
with a Li-Cor Odyssey Imaging System (Li-Cor Bio-
sciences, Lincoln, NE).
Primary antibodies that were utilized included antibodies
specific to total and phosphorylated terminal MAP
kinases (ERK1/2, JNK 1/2, and p38), and caspases 8 and
3. [Antibodies to ERK 1/2 (sc492), pERK (sc7383), JNK1/
2 (sc571), and pJNK (sc625) were obtained from Santa
Cruz Biotechnologies, Inc., Santa Cruz CA; antibodies to
active caspase 3 (55–9565) and active caspase 8 (51–
8125) were obtained from BD Biosciences Pharmingen,
San Jose CA]. All primary antibodies were used at a 1:1000
dilution.
Statistics
All data are displayed as mean ± standard error of the
mean (S.E.M.). Comparisons between the OMDM and
OSDM and their controls were made using an unpaired t-
test. Significant differences were identified at the p < 0.05
levels
Results
Maternal data
Blood glucose was measured twice daily between day 12
of pregnancy and delivery to monitor the effectiveness of
insulin therapy in the moderately diabetic model. Gener-
ally, blood glucose values were in the 200–400 mg/dl
range, although higher and lower values occurred. Peri-
odic screening for ketones in the pregnant dams was neg-
ative.
In the severely diabetic model, maternal blood glucose
levels were measured to document hyperglycemia on day
15 of gestation and postnatal day 1. Blood glucose ranged
from 83 – 104 mg/dl in control rats and 458 - >600 mg/
dl in diabetic dams at both time points, with the majority
of the values >600 mg/dl. Blood from a subset of maternal
rats obtained on the day of delivery (n = 3 control, 3 dia-
betic) was positive for moderate ketones in all diabetic
samples and negative in control samples. In addition,
maternal severely diabetic rats generally appeared cachec-
tic, although morphometric measurements on the moth-
ers were not made.
Morphometric data
Maternal diabetes affected the body weight and heart
weight of the rat pups (Table 1). The OMDM had
increased heart weight and heart weight to body weight
ratio (HW:BW) at NB1 when compared to control ani-
mals. At NB21, there continued to be relative organomeg-
ally with an increased HW:BW in the OMDM. There was
not a significant difference in the body weight of OMDM
and control animals at either time point.
Conversely, the OSDM had decreased body weight and
decreased heart weight when compared to control ani-Cardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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mals at NB1. There was relative sparing of myocardial
mass when compared to body weight resulting in an
increased HW:BW at this time point. Despite normaliza-
tion of the absolute heart weight and body weight by
NB21, the increase in the HW:BW persisted in the OSDM
when compared to controls.
Echo data
Maternal diabetes also affected the left ventricular size and
function of the rat pups, as determined by echocardiogra-
phy. The OMDM and control animals had similar left ven-
tricular size and ejection fraction at both the NB1 and
NB21 time points (Table 2). The newborn OSDM, how-
ever, had a significantly decreased left ventricular ejection
fraction compared to controls. This was accompanied by
a significant increase in left ventricular end systolic vol-
ume in the OSDM (control: 2.0 ± 0.3 mcl; OSDM: 4.3 ±
1.0 mcl; p < 0.05) suggesting that the OSDM developed a
dilated cardiomyopathy. By 21 days of age, there was
echocardiographic resolution of the cardiomyopathy in
the OSDM, with normalization of the ejection fraction
(Table 2) and end systolic volume (control: 33 ± 12 mcl;
OSDM: 24 ± 8 mcl; p = 0.6).
No significant differences were seen in echocardiographic-
calculated left ventricular mass between controls and
ODM at both ages in either the severely or moderately dia-
betic groups (Table 2). Of note, the m-mode method of
calculating ejection fraction that was used in the OMDM
gave consistently lower values compared to the modified
Simpson's method from 2-D images used in the OSDM
animals.
MAPK Pathways
Maternal diabetes altered MAPK protein activation in the
newborn OMDM and OSDM with evidence of continued
ventricular remodeling at NB21. Steady state levels of the
total and activated MAPK proteins were measured using
Western blot analysis. When present, ERK isomers were
analyzed as a single band. A similar pattern of MAPK pro-
tein activation was seen in the offspring diabetic mothers,
regardless of severity (Figures 1 and 2). In both OMDM
Table 1: Morphometric Data from offspring of control and diabetic mothers.
Offspring of Moderately
Diabetic Mothers
Offspring of Severely
Diabetic Mothers
Body
Weight
(g)
Heart
Weight
(mg)
HW/BW
(mg/g)
Body
Weight
(g)
Heart
Weight
(mg)
HW/BW
(mg/g)
NB1 Control 7.0 ± 0.1 43 ± 1 6.1 ± 0.1 8.3 ± 0.1 49 ± 1 5.8 ± 0.1
NB1 ODM 7.1 ± 0.1 48 ± 1* 6.7 ± 0.1* 5.9 ± 0.2* 39 ± 2* 6.6 ± 0.2*
NB21 Control 58.6 ± 1.1 294 ± 7 5.0 ± 0.1 43.5 ± 3.2 214 ± 11 5.0 ± 0.1
NB21 ODM 55.7 ± 1.1 309 ± 6 5.6 ± 0.1* 41.9 ± 6.2 230 ± 16 5.6 ± 0.4*
All values are mean ± SE; NB1 = 1 day old animals, NB21 = 21 day old animals, HW/BW – heart weight to body weight ratio, ODM – offspring of 
diabetic mothers. *p < 0.05 versus control by unpaired t-test.
Table 2: Echocardiographic data from offspring of control and diabetic mothers.
EF – Moderately Diabetic 
Model
(%)
EF – Severely Diabetic Model
(%)
LVM – Moderately Diabetic 
Model
(mg)
LVM – Severely Diabetic 
Model
(mg)
NB1 Control 73 ± 4 88 ± 1 38 ± 4 31 ± 2
NB1 ODM 69 ± 3 76 ± 4* 8 ± 3 33 ± 5
NB21 Control 68 ± 4 80 ± 4 197 ± 13 192 ± 7
NB21 ODM 70 ± 2 86 ± 5 220 ± 16 192 ± 12
All values are mean ± SE; NB1 – 1 day old animals, NB21 – 21 day old animals, EF = ejection fraction, LVM = left ventricular mass. *p < 0.05 versus 
control by unpaired t-testCardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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and OSDM, animals at 21 days of age were found to have
significantly increased activation of both JNK and ERK.
No change was found in pJNK or pERK levels in NB1 ani-
mals from either model except a small but significant
decrease in pJNK in the NB1 OSDM (Figure 1).
Total MAPK protein levels remained fairly stable with sig-
nificant differences between offspring of diabetic mothers
and control animals only found for JNK in NB21 and ERK
in NB1 of OSDM.
Although not shown, low levels of p38 and phosphor-
ylated p38 were found in all animals studied although no
differences were seen between offspring of diabetic moth-
ers and control animals from either model.
Apoptosis protein levels
The levels of active, or cleaved, caspase 3 and caspase 8
were determined for animals from both models and at
both time points. In NB1 pups, levels of all measured pro-
teins were similar between groups, although small but sig-
nificant decreases in caspase 3 and 8 were seen in the NB1
OSDM (Figure 3). By 21 days of age, however, apoptotic
pathways were found to be significantly activated (Figure
3). In the OMDM, active caspase 8 levels were signifi-
cantly elevated at 21 days of age. Both active caspase 3 and
active caspase 8 protein levels were significantly elevated
in the NB21 pups that were OSDM.
Discussion
Maternal diabetes creates an adverse environment for fetal
development resulting in a number of anatomic, hemato-
logic, and physiologic abnormalities in the newborn [19].
The effects of uncontrolled or long-standing diabetes on
the fetus and the neonate are quite different from those
found in well-controlled maternal diabetes. Prior to the
use of insulin, few diabetic women conceived and even
fewer carried a pregnancy to term [19]. In performing a
Total and active c-Jun NH2-terminal kinase (JNK, and pJNK, respectively) protein levels were measured by immunoblot in  hearts from control (C) and offspring of either moderately or severely diabetic dams (D) at 1 and 21 days of life (NB1 and  NB21, respectively) Figure 1
Total and active c-Jun NH2-terminal kinase (JNK, and pJNK, respectively) protein levels were measured by 
immunoblot in hearts from control (C) and offspring of either moderately or severely diabetic dams (D) at 1 
and 21 days of life (NB1 and NB21, respectively). The immunoblots are shown at the top with the bar graphs indicating 
protein levels expressed in arbitrary units. Molecular weights: JNK – 48 kD, pJNK – 46 kD. *p < 0.05 versus control value by 
unpaired t-test.Cardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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post mortem quantitative morphologic study on infants
of diabetic mothers and comparing them to controls
matched for gestational and postnatal age, Naeye identi-
fied two populations of infants of diabetic mothers [3].
The first group of infants had a body weight that was
141% of the control values. In addition, these infants had
organomegally with heart weights that were 174% of the
control values. This group likely represented mothers with
residual insulin function whose serum glucose values
were elevated but did not become ketotic. The second
group consisted of underweight infants with body weights
61% of control values and heart weights that were 51% of
controls. This group was likely more severely ill and was
thought to have placental insufficiency due to their degree
of illness. The decrease in cardiac mass in the newborns
was attributed to myocyte death [3].
The findings of our study are consistent with Naeye's
observations. Specifically, OSDM had a decrease in body
weight and heart weight when compared to control pups.
Due to a relative sparing of heart weight compared to
body weight, however, there was a significant increase in
the heart weight to body weight ratio at both time points.
These findings were associated with decreased left ven-
tricular systolic function echocardiographically in the
immediate newborn period. The difference between con-
trol and OSDM heart weight-to-body weight and cardiac
function is likely related to the poorly controlled maternal
diabetes and associated maternal anorexia, undernutri-
tion and/or placental insufficiency. This theory is sup-
ported by both human and animal data.
Echocardiographic studies have found a relative sparing of
cardiac weight when compared to body weight in human
Total and active extracellular signal-regulated kinase (ERK, and pERK, respectively) protein levels were measured by immuno- blot in hearts from control (C) and offspring of either moderately or severely diabetic dams (D) at 1 and 21 days of life (NB1  and NB21, respectively) Figure 2
Total and active extracellular signal-regulated kinase (ERK, and pERK, respectively) protein levels were meas-
ured by immunoblot in hearts from control (C) and offspring of either moderately or severely diabetic dams 
(D) at 1 and 21 days of life (NB1 and NB21, respectively). In NB1 myocardial samples, ERK1 and ERK2 were both seen 
and quantitated as a single band. The immunoblots are shown at the top with the bar graphs indicating protein levels expressed 
in arbitrary units. Molecular weights: ERK1 – 42 kD, ERK2 – 44 kD, pERK – 43 kD. *p < 0.05 versus control value by unpaired 
t-test.Cardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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pregnancies complicated by poorly controlled maternal
diabetes and intrauterine growth restriction (IUGR) [20].
IUGR alone is also associated with decreased cardiac func-
tion that worsens with advancing gestation [21].
Several studies have described the cardiomyopathy seen
in the macrosomic offspring of mothers with moderately
well controlled gestational diabetes [2,4-6,22]. The HCM
in these infants is characterized by asymmetric hypertro-
phy of the ventricular septum [6]. While increased septal
thickness was not found by echo in the OMDM in this
study, an increase in cardiac mass was seen at one-day of
age in the OMDM compared to controls. As in humans,
variability in septal thickness between animals may have
prevented the identification of significant differences in
this measurement between groups.
While multiple studies have described the morphologic
and histologic characteristics of the cardiomyopathy seen
in infants of diabetic mothers, no study to our knowledge
has described the molecular mechanisms that correlate
with the cardiomyopathic changes. The striking finding of
this study is that regardless of the extent of intrauterine
insult to the heart due to maternal hyperglycemia, the
postnatal remodeling process was accompanied by activa-
tion of the MAPK signaling pathways. The MAPK signal-
ing pathways have multiple effects on cardiac myocyte
growth, proliferation and apoptosis and have been impli-
cated in other forms of cardiomyopathy [14,15]. We
found that at one day of age, the hypertrophic cardiomy-
opathy in OMDM and the dilated cardiomyopathy in
OSDM was associated with limited changes in MAPK acti-
vation, although small changes were found at NB1 in
OSDM in total ERK and active (phosphorylated) JNK (Fig-
ures 1 and 2). In both models, the resolution of the cardi-
omyopathy at NB21 was associated with significant up
regulation of both active JNK (pJNK) and active ERK
(pERK). Levels of active P38 were unchanged at both time
Active Caspase 3 and active Caspase 8 protein levels were measured by immunoblot in hearts from control (C) and offspring  of either moderately or severely diabetic dams (D) at 1 and 21 days of life (NB1 and NB21, respectively) Figure 3
Active Caspase 3 and active Caspase 8 protein levels were measured by immunoblot in hearts from control 
(C) and offspring of either moderately or severely diabetic dams (D) at 1 and 21 days of life (NB1 and NB21, 
respectively). The immunoblots are shown at the top with the bar graphs indicating protein levels expressed in arbitrary 
units. Molecular weights: caspase 3 – 35 kD, caspase 8 – 55 kD. *p < 0.01 versus control value by unpaired t-test.Cardiovascular Diabetology 2009, 8:43 http://www.cardiab.com/content/8/1/43
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points. The downstream targets of these signaling proteins
that contribute to the cardiac remodeling in the offspring
of diabetic dams are currently not known.
ERK has the most well defined role of the MAPK proteins.
In general, ERK is considered to be progrowth, promoting
hyperplasia in uninucleated myocytes and hypertrophy in
binucleated myocytes [11,23]. Bueno et. al. examined the
effects of ERK activation in transgenic mice with cardiac
specific expression of the ERK activator, MEK1. In addi-
tion, they activated ERK in cultured myocytes by transfect-
ing with MEK1 adenovirus. Both experiments
demonstrated that the MEK1/ERK signaling pathway
stimulated physiologic hypertrophy associated with aug-
mented cardiac function and partial resistance to apopto-
sis [24]. In addition, ERK was found to play a key role in
IGF-1 induced cardiac myocyte proliferation [25]. The sig-
nificant increase in pERK in NB21 offspring in both mod-
els may reflect a general decrease in myocyte cell number
in utero due to maternal hyperglycemia that is compen-
sated for by an increase in pERK-driven myocyte prolifer-
ation postnatally. Measurement of myocyte size in the
OMDM would help to define whether individual myocyte
hypertrophy is present in these animals, which would be
necessary if cardiac hypertrophy, as seem in the NB1 pups,
was accompanied by decreased myocyte number.
The roles of JNK and p38 are less well defined than that of
ERK. As recently reviewed by Liang and Molkentin, p38
and JNK have differing roles in vivo and in vitro [26]. In
vivo, activation of p38 and JNK appears to inhibit hyper-
trophy and promote apoptosis, while in vitro, activation of
these pathways appears to promote hypertrophy
[8,12,27,28]. Although phosphorylated p38 protein levels
were unchanged, there was a striking increase in the levels
of active JNK (pJNK) at NB21 in both models. Thus, at 21
days of age there appears to be activation of competing
regulatory proteins in the hearts of the offspring of dia-
betic mothers, regardless of the degree of maternal hyper-
glycemia, with ERK being prohypertrophic and
antiapoptotic and JNK being antihypertrophic and proap-
optotic. Whether these competing influences work to
appropriately couple myocyte hyperplasia with myocyte
apoptosis, as has been suggested occurs during normal
cardiac development [29], is not known.
We found indications that activation of apoptotic path-
ways was important to the cardiac remodeling seen in
both OMDM and OSDM (Figure 3). Up-regulation of
apoptosis was assessed by measuring protein levels of the
initiator caspase 8 and the effector caspase 3. In the
OMDM, a significant increase was found in active caspase
8 while both active caspase 3 and 8 were significantly
increased in OSDM in NB21 hearts. This suggests that
despite activation of competing MAP kinase signaling
pathways in the NB21 offspring of diabetic mothers, the
JNK signaling to promote apoptosis was more robust than
ERK signaling.
Limitations
The results of this study may have been affected by the
overall health of the diabetic dams, particularly in the
severely hyperglycemic model where they were likely mal-
nourished due to illness-induced anorexia. These issues
are, however, clinically relevant and are seen in human
pregnancies complicated by poorly controlled diabetes.
Direct comparison of the consequences on the two mod-
els on the offspring is impacted by the different duration
of hyperglycemia. The severely diabetics animals received
streptozotocin on day 7 of pregnancy while the animals in
the moderately diabetic model were made diabetic on day
12. It is interesting that similar changes in MAPK activa-
tion were found in the offspring suggesting that, despite
the differing exposures to hyperglycemia, activation of the
MAPK pathways may be common response in postnatal
cardiac remodeling. However, limited time points were
evaluated. Other important changes in the levels of inac-
tive and active MAPK and apoptotic proteins could have
occurred at time points not represented by our measure-
ments.
Conclusion
The degree of maternal hyperglycemia during pregnancy
greatly impacts the type of cardiomyopathy found in the
newborn. Moderately well controlled hyperglycemia, as
occurs with most human pregnancies, results in hypertro-
phy of the neonatal heart. When the hyperglycemia is
poorly controlled and impacts maternal, and likely fetal,
nutrition, a dilated cardiomyopathy results. Both the car-
diomyopathies are transient, and in the rat, have largely
resolved by three weeks of age. The similar activation of
the MAPK signaling and apoptotic pathways in these two
models suggests that these pathways may have a wide-
ranging impact on the ability of the heart to remodel.
Exploration of MAP kinase and apoptotic activity in the
remodeling process that occurs with other cardiomyopa-
thies may help to understand how the heart responds to
other insults that impact cardiac structure and function.
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